H1 2026 Bio VC Investment: Surface-Level Rebound and Concentration on Megarounds

In the first half of 2026, biotech venture capital (VC) investment reached at least $9.1 billion USD across 68 companies, marking the highest level since 2022. However, a significant concentration occurred, with 76% of total funding directed towards megarounds (deals exceeding $100 million). Notably, Isomorphic Labs, a subsidiary of Google focused on AI-driven drug discovery, secured a massive $2.1 billion funding round, significantly skewing the overall figures. As investors prioritize larger assets with higher survival potential amidst macroeconomic uncertainty, early-stage startups face relative disadvantages despite the apparent positive trend.

Preference for Clinically Validated Assets and Concerns about Disconnection from Early-Stage Innovation Pipelines

Approximately two-thirds (42 companies) of the companies that secured VC funding in the first half of the year already possess clinical trial-stage pipelines. For example, cAMPfield Therapeutics raised $180 million in Series A funding to support a global Phase 2 clinical trial for prifemilast, its PDE4B selective inhibitor for ulcerative colitis. Solstice Oncology also secured funding to advance a Phase 1/2 clinical trial for porustobart, a CTLA-4 targeting antibody acquired from Harbour BioMed. As investors focus on later-stage clinical assets to mitigate risk, early-stage startups are experiencing severe funding shortages, which could ultimately disrupt the supply of new drugs (R&D pipeline).

Selective Exit Market Driven by Large IPOs and Active M&A

This trend of capital concentration towards later-stage assets is further fueled by strong exit performance in the IPO and M&A markets. In the first half of the year, 13 biotech companies went public through IPOs, raising a total of $4.5 billion. Kailera Therapeutics (KLRA) and Parabilis Medicines (PBLS) successfully raised $625 million and $670 million, respectively. The M&A market also saw 38 deals completed in the first half of the year, the fastest pace in seven years. With two-thirds of M&A deals exceeding $1 billion and four deals exceeding $10 billion, the value of large assets has soared, but this benefit has not extended to the early-stage venture ecosystem, exacerbating the polarization.

Strong Performance in Immunotherapy and Oncology Modalities, Weakness in Cell and Gene Therapies

In terms of therapeutic areas and modalities, a clear concentration of capital towards safer investment options is observed. Over 40% of investment deals in the first half of the year focused on companies developing immunotherapies and oncology drugs, with small molecule and biologics sectors each attracting over $2 billion in investment. In contrast, cell and gene therapy (CGT) and nucleic acid therapies, which were once considered promising next-generation technologies, have remained stagnant, with annual funding remaining around $2 billion for several years. This is due to the combination of poor sales performance and clinical safety concerns surrounding gene editing therapies like Casgevy, as well as stricter regulations from the U.S. Food and Drug Administration (FDA), which have dampened investor sentiment. As a result, the market is focusing capital on proven, existing technologies.